Skip to main content

Research News

 

Clinical courses

 

Clinical research courses

  • How Omicron dodges the immune system

    The current wave of COVID-19 highlights a particularly high risk of reinfection by the Omicron variant of SARS-CoV-2. Why is this? A team from the Centre for Emerging Viral Diseases of the University of Geneva (UNIGE) and of the Geneva University Hospital (HUG) analysed the antibody neutralisation capacity of 120 people infected with the original SARS-CoV-2 strain, or with one of its Alpha, Beta, Gamma, Delta, Zeta or Omicron (sub-variant BA.1) variants.

  • Study could help better management of Alzheimer’s patients

    A team of researchers at the Bengaluru-based Indian Institute of Science (IISc) has developed a GPU-based machine learning algorithm that promises to help identify early signs of aging or deterioration of brain function before they manifest behaviourally in Alzheimers patients.

  • Higher Protein Intake While Dieting Leads to Healthier Eating

    Eating a larger proportion of protein while dieting leads to better food choices and helps avoid the loss of lean body mass, according to a Rutgers study.

    An analysis of pooled data from multiple weight-loss trials conducted at Rutgers shows that increasing the amount of protein even slightly, from 18 percent of a person’s food intake to 20 percent, has a substantial impact on the quality of the food choices made by the person. The study was published in the medical journal Obesity.

  • Patients treated with monoclonal antibodies during COVID-19 delta surge had low rates of severe disease ; study finds

    A study of 10,775 high-risk adult patients during the COVID-19 delta variant surge in late 2021 finds that treatment with one of three anti-spike neutralizing monoclonal antibodies for mild to moderate symptoms led to low rates of severe disease, hospitalization, ICU admission and mortality, according to Mayo Clinic researchers.

  • COVAXIN induces higher neutralising antibody response in children, says study

    New study published in Lancet Infectious Diseases suggests that Bharat Biotech COVID19 vaccine, COVAXIN induces higher neutralising antibody response in children aged 2-18 years. The company had conducted an age de-escalation study to assess the safety, reactogenicity, and immunogenicity of an inactivated COVID-19 vaccine, COVAXIN.

  • TB treatment during pregnancy is safe for mum and baby : Study finds

    Seven out of 10 pregnant women were cured of their multidrug-resistant tuberculosis and delivered healthy babies after taking a medication that had previously been considered unsafe in pregnancy, a new Curtin and Telethon Kids Institute study has found.

    Published in JAMA Network Open, the study examined the experiences of 275 pregnant women with multidrug-resistant tuberculosis living in South Africa, Peru, Brazil, Iran and Uganda.

  • Researchers develop blood test to predict liver cancer risk

    An estimated one-quarter of adults in the U.S. have nonalcoholic fatty liver disease (NAFLD), an excess of fat in liver cells that can cause chronic inflammation and liver damage, increasing the risk of liver cancer. Now, UT Southwestern researchers have developed a simple blood test to predict which NAFLD patients are most likely to develop liver cancer.

  • Rethinking the rabies vaccine

    Rabies virus kills a shocking 59,000 people each year, many of them children. Some victims, especially kids, don’t realize they’ve been exposed until it is too late. For others, the intense rabies treatment regimen is out of the question: treatment is not widely available and the average 3,800 Dollar expense poses unthinkable economic burden for most people around the world.

  • Why vaccination against malaria quickly loses its protective effect

    Scientists from the German Cancer Research Center (DKFZ) studied the human immune response after immunization with the malaria pathogen Plasmodium falciparum. Their goal was to find out against which protein components the T helper cells induced in this way are directed. To the researchers' surprise, the T helper cells reacted exclusively to the protein sequence of the vaccine strain and showed hardly any cross-reactivity with the naturally occurring pathogen variants.

  • Stress Protein in Fibroblasts May Be a Good Target for Future Cancer Drugs, Study Finds

    A stress protein that is overactive in many types of tumor cells also has a key role in tumor-supporting cells called fibroblasts, and may be a good target for future cancer treatments, suggests a study from researchers at the Perelman School of Medicine at the University of Pennsylvania.

Subscribe to Research News